Market Cap (In USD)
8.5 Billion
Revenue (In USD)
124.79 Million
Net Income (In USD)
4.34 Billion
Avg. Volume
6.17 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 9.69-13.055
- PE
- -
- EPS
- -
- Beta Value
- 1.243
- ISIN
- BMG762791017
- CUSIP
- G76279101
- CIK
- 1635088
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Matthew Gline
- Employee Count
- -
- Website
- https://roivant.com
- Ipo Date
- 2020-12-08
- Details
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
More Stocks
-
1942Kandenko Co.,Ltd.
1942
-
ORPB
-
EVGNEvogene Ltd.
EVGN
-
ASGOFAsante Gold Corporation
ASGOF
-
DIIBFDorel Industries Inc.
DIIBF
-
ACHRArcher Aviation Inc.
ACHR
-
3796e-Seikatsu Co.,Ltd.
3796
-
CACC